Alex Parra

Getafe, Spain

PAPER Carracedo M, Pawelzik SC, Artiach G, Pouwer MG, Plunde O, Saliba-Gustafsson P, Ehrenborg E, Eriksson P, Pieterman E, Stenke L, Princen HM, Franco-Cereceda A, Bäck M

The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.

Br J Pharmacol. 2022 Oct;179(19):4709-4721. Epub 2022 Jul 19 PubMed.

Markus Damme on Divergent and Convergent TMEM106B Pathology in Murine Models of Neurodegeneration and Human Disease

COMMENT Interesting story, if true: So far, TMEM106B fibrils have not been demonstrated in mice. Some critical controls are missing in this preprint: the current set of antibodies cannot distinguish between fibrillary/physiological (natively folded) TMEM106B. The

Paul Maruff

Cogstate

Cheng-Chun Wu

I-Shou University
Kaohsiung City, Taiwan, Province of China

Nikolaos K. Robakis on Hypercholesterolemia and Alzheimer's Disease: Unraveling the Connection and Assessing the Efficacy of Lipid-Lowering Therapies.

COMMENT This review article on hypercholesterolemia and Alzheimer's disease is an excellent contribution to understanding the complex link between cholesterol management and AD pathology, providing valuable insights for both clinicians and researchers. Here

Seongho Seo

Pai Chai University
Daejeon, Korea, Republic of

ALIA-1758

THERAPEUTICS AbbVie Aliada Therapeutics Immunotherapy (passive) Amyloid-Related In May 2024, Aliada began Phase 1 with a single-dose trial in healthy participants. It will test the safety, tolerability, and pharmacokinetics of intravenous or subcutaneous doses of ALIA

Ling Hwang

Anglia Ruskin University
United Kingdom

Barry Littleton

Stephenville , United States

Donanemab: Small Tweak in Titration, Big Gain in Safety?

CONFERENCE COVERAGE 2024-11-08 Conference Coverage Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab  at this year’s Clinical Trials on Alzheimer’s Disease conference, held October 29-Nov

NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed) (PAR-25-234)

GRANT Friday, November 8, 2024- 2:45pm National Institute of Neurological Disorders and Stroke Multiple due dates; see announcement. https://grants.nih.gov/grants/guide/pa-files/PAR-25-234.html 08 Jan 2028

Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) (PAS-25-190)

GRANT Friday, November 8, 2024- 2:45pm National Institutes of Health Multiple due dates; see announcement. https://grants.nih.gov/grants/guide/pa-files/PAS-25-190.html 06 Nov 2027

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) (PAR-25-225)

GRANT Friday, November 8, 2024- 2:30pm National Institute of Neurological Disorders and Stroke Multiple due dates; see announcement. https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html 21 Oct 2027

Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed) (PAR-25-198)

GRANT Friday, November 8, 2024- 2:15pm National Institutes of Health Multiple due dates; see announcement. https://grants.nih.gov/grants/guide/pa-files/PAR-25-198.html 08 Jan 2026